menu
    • menu
    [{"orgOrder":0,"company":"Coda Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Coda Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coda Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Coda Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coda Biotherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Coda Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Coda Biotherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Coda Biotherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Coda Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Ligand gated ion channel","graph1":"Neurology","graph2":"Preclinical","graph3":"Coda Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Coda Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Coda Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coda Biotherapeutics","sponsor":"Facial Pain Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ligand gated ion channel","graph1":"Neurology","graph2":"Preclinical","graph3":"Coda Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coda Biotherapeutics \/ Facial Pain Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Coda Biotherapeutics \/ Facial Pain Research Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by Coda Biotherapeutics

    Menu

    Coda Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Coda Biotherapeutics

                            U.S.A arrow
                            ACS GCI
                            Not Confirmed

                            Coda Biotherapeutics

                            U.S.A arrow
                            ACS GCI
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CODA Biotherapeutics Announces New Preclinical Data From Epilepsy Program Showing Significant Correlation Betw...

                            Details : The results showed that CODA's lead receptor AAV Based Therapy, and activator drug significantly reduces seizure frequency in two different models of focal epilepsy - electrical seizure threshold and kainic acid induction.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 06, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Coda Biotherapeutics

                            U.S.A arrow
                            ACS GCI
                            Not Confirmed

                            Coda Biotherapeutics

                            U.S.A arrow
                            ACS GCI
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CODA Biotherapeutics' Chemogenetic Gene Therapy Platform Can Control Focal Seizures In Vivo

                            Details : The results showed efficacy for AAV Vector based gene therapy approach in controlling spontaneous seizures in a model system that replicates many features of human temporal lobe epilepsy can control focal seizures in vivo.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 12, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Coda Biotherapeutics

                            U.S.A arrow
                            ACS GCI
                            Not Confirmed

                            Coda Biotherapeutics

                            U.S.A arrow
                            ACS GCI
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $0.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CODA Biotherapeutics Receives Grant from the NIH to Help Advance its Next-Generation Gene Therapy-Mediated Che...

                            Details : Funding will be used to support CODA's plans to evaluate and advance the Company's unique receptor-ligand pairs toward the clinic for the treatment of neuropathic pain.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 11, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $0.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Coda Biotherapeutics

                            U.S.A arrow
                            ACS GCI
                            Not Confirmed

                            Coda Biotherapeutics

                            U.S.A arrow
                            ACS GCI
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Facial Pain Research Foundation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CODA Biotherapeutics Announces Research Collaboration With The Facial Pain Research Foundation

                            Details : Strategic partnership supports CODA's efforts to develop gene-therapy mediated treatments and cures for trigeminal neuralgia and related neuropathic pain.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 20, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Facial Pain Research Foundation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth